Drugs in R & D

, Volume 6, Issue 6, pp 337–344 | Cite as

Topical Ketoprofen Patch

  • Bernard MazièresEmail author
Review Article


Although oral nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in the treatment of a variety of acute and chronic pain conditions, their use may be associated with serious systemic adverse effects, particularly gastrointestinal disorders. In order to minimise the incidence of systemic events related to such agents, topical NSAIDs have been developed. Topical NSAIDs, applied as gels, creams or sprays, penetrate the skin, subcutaneous fatty tissue and muscle in amounts that are sufficient to exert a therapeutic effect on peripheral and central mechanisms in the absence of high plasma concentrations. Data indicate that topical NSAIDs are effective at relieving pain in a number of acute and chronic pain indications.

This review article discusses the pharmacokinetics, efficacy and tolerability of a new formulation of ketoprofen available as a topical patch. The topical patch containing ketoprofen 100mg as the active principle has been developed using a novel delivery system that dispenses therapeutic doses of the drug directly to the site of injury.

Pharmacokinetic data indicate that although plasma levels of ketoprofen are higher when the drug is administered as a patch versus a gel, the total systemic bioavailability of ketoprofen 100mg administered via a patch is no more than 10% of that reported for ketoprofen 100mg administered orally. Because the patch facilitates ketoprofen delivery over a 24-hour period, the drug remains continually present in the tissue subjacent to the site of application. High tissue but low plasma ketoprofen concentrations mean that while tissue concentrations are high enough to exert a therapeutic effect, plasma concentrations remain low enough to not result in systemic adverse events caused by elevated serum NSAID levels. Phase III clinical trials in patients with non-articular rheumatism and traumatic painful soft tissue injuries showed that the topical ketoprofen patch was significantly more effective than placebo at reducing pain during daily activities and spontaneous pain after 7 days’ treatment. Moreover, the topical ketoprofen patch was well tolerated; adverse events were primarily cutaneous in nature and occurred in a similar number of ketoprofen and placebo recipients suggesting that these events were related to the patch itself rather than the active ingredient. The incidence of gastrointestinal adverse events was low (<8% of all patients), and occurred in a similar proportion of patients receiving ketoprofen and placebo.

Thus, the topical ketoprofen patch appears to be a simple, effective and safe therapeutic option for the treatment of local painful inflammation.


Piroxicam Ketoprofen Gastrointestinal Adverse Event Patellar Tendinopathy Topical NSAID 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No external funding was provided for this study. BM was the principal investigator for two trials of topical ketoprofen patch referred to in this review and received fees for writing the protocols, participating in the blind reviews, supervising the final reports and writing the two papers. BM has also undertaken educational activities with the Zambon Group, but is totally independent of the company and declares no conflict of interest.


  1. 1.
    Moore RA, Tramer MR, Carroll D, et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316 (7128): 333–8PubMedCrossRefGoogle Scholar
  2. 2.
    McCormack K, Brune K. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs: a survey of their analgesic efficacy. Drugs 1991; 41 (4): 533–47PubMedCrossRefGoogle Scholar
  3. 3.
    Bannwarth B, Demotes-Mainard F, Schaeverbeke T, et al. Where are peripheral analgesics acting? Ann Rheum Dis 1993; 52 (1): 1–4PubMedCrossRefGoogle Scholar
  4. 4.
    Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl. 5: 13–23PubMedCrossRefGoogle Scholar
  5. 5.
    Wynne HA, Campbell M. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmacoeconomics 1993; 3 (2): 107–23PubMedCrossRefGoogle Scholar
  6. 6.
    Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000; 60 (3): 555–74PubMedCrossRefGoogle Scholar
  7. 7.
    Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 1995; 49 (1): 33–5PubMedGoogle Scholar
  8. 8.
    Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004; 5 (1): 10PubMedCrossRefGoogle Scholar
  9. 9.
    Rolf C, Movin T, Engstrom B, et al. An open, randomized study of ketoprofen in patients in surgery for Achilles or patellar tendinopathy. J Rheumatol 1997; 24 (8): 1595–8PubMedGoogle Scholar
  10. 10.
    Rolf C, Engstrom B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford) 1999; 38 (6): 564–7CrossRefGoogle Scholar
  11. 11.
    Jokhio IA, Siddiqui KA, Waraich T, et al. Study of efficacy and tolerance of ketoprofen and diclofenac sodium in the treatment of acute rheumatic and traumatic conditions. J Pak Med Assoc 1998; 48 (12): 373–6PubMedGoogle Scholar
  12. 12.
    Patel RK, Leswell PF. Comparison of ketoprofen, piroxicam, and diclofenac gels in the treatment of acute soft-tissue injury in general practice. General Practice Study Group. Clin Ther 1996; 18 (3): 497–507PubMedCrossRefGoogle Scholar
  13. 13.
    Orudis (ketoprofen) Prescribing Information. Wyeth 2003Google Scholar
  14. 14.
    Cordero JA, Camacho M, Obach R, et al. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm 2001; 51 (2): 135–42PubMedCrossRefGoogle Scholar
  15. 15.
    Cordero JA, Alarcon L, Escribano E, et al. A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci 1997; 86 (4): 503–8PubMedCrossRefGoogle Scholar
  16. 16.
    Flouvat B, Roux A, Delhotal-Landes B. Pharmacokinetics of ketoprofen in man after repeated percutaneous administration. Arzneimittel Forschung 1989; 39 (7): 812–5PubMedGoogle Scholar
  17. 17.
    Cannavino CR, Abrams J, Palinkas LA, et al. Efficacy of transdermal ketoprofen for delayed onset muscle soreness. Clin J Sport Med 2003; 13 (4): 200–8CrossRefGoogle Scholar
  18. 18.
    Rovati LC, Setnikar I, Genazzani AR. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group. Gynecol Endocrinol 2000; 14 (4): 282–91PubMedCrossRefGoogle Scholar
  19. 19.
    Notelovitz M, Cassel D, Hille D, et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2000; 182 (1 Pt 1): 7–12PubMedCrossRefGoogle Scholar
  20. 20.
    Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77 (2 Suppl. 2): S13–8CrossRefGoogle Scholar
  21. 21.
    Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285 (18): 2347–54PubMedCrossRefGoogle Scholar
  22. 22.
    Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44 (3): 498–529PubMedCrossRefGoogle Scholar
  23. 23.
    Hays JT, Croghan IT, Schroeder DR, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health 1999; 89 (11): 1701–7PubMedCrossRefGoogle Scholar
  24. 24.
    Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13 (2): 238–46PubMedCrossRefGoogle Scholar
  25. 25.
    Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322 (7295): 1154–8PubMedCrossRefGoogle Scholar
  26. 26.
    Mystakidou K, Befon S, Kouskouni E, et al. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 2001; 21 (3C): 2225–30PubMedGoogle Scholar
  27. 27.
    Mertin D, Cordes G, Heiling T. Ketoprofen TDS, a new approach for the therapy of rheumatism and sport injuries [abstract]. Proceedings of the 2nd World Meeting APGI/APV; 1998 May 25–28; Paris, France. 893–4Google Scholar
  28. 28.
    Klaffenbach P, Vollmer U. In vitro percutaneous absorption in isolated skin: test-product ketoprofen TDS patch in comparison with ketoprofen gel. Report on file September 2000Google Scholar
  29. 29.
    Osterwalder A, Reiner V, Reiner G, et al. Tissue absorption and distribution of ketoprofen after patch application in subjects undergoing knee arthroscopy or endoscopic carpal ligament release. Arzneimittel Forschung 2002; 52 (11): 822–7PubMedGoogle Scholar
  30. 30.
    Crestani S, Ismaili S. IPAS-KETO/TDS-280-01, Final report: systemic bioavailability study of ketoprofen administered to healthy volunteers as TDS patch (test formulation) vs gel (reference formulation). Report on file June 2002Google Scholar
  31. 31.
    Verbeeck RK, Corman CL, Wallace SM, et al. Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. Eur J Clin Pharmacol 1988; 35 (5): 521–7PubMedCrossRefGoogle Scholar
  32. 32.
    Data on file, Zambon Group, Bresso, ItalyGoogle Scholar
  33. 33.
    Mazieres B, Rouanet S, Guillon Y, et al. Topical ketoprofen patch in the treatment of tendinitis: a randomized, double blind, placebo controlled study. J Rheumatol 2005; 32: 1563–70PubMedGoogle Scholar
  34. 34.
    Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344 (21): 1594–602PubMedCrossRefGoogle Scholar
  35. 35.
    Mazieres B, Rouanet S, Velicy J, et al. Topical ketoprofen patch (100mg) in the treatment of ankle sprain: a randomized, double-blind, placebo-controlled study. Am J Sports Med 2005; 33: 515–23PubMedCrossRefGoogle Scholar
  36. 36.
    Lee JS, Hobden E, Stiell IG, et al. Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med 2003; 10 (10): 1128–30PubMedCrossRefGoogle Scholar
  37. 37.
    Cepeda MS, Africano JM, Polo R, et al. What decline in pain intensity is meaningful to patients with acute pain? Pain 2003; 105 (1–2): 151–7PubMedCrossRefGoogle Scholar
  38. 38.
    US Food and Drug Administration. Guidelines for the clinical value of analgesic drugs. 1992Google Scholar
  39. 39.
    Dionne RA, Gordon SM, Tahara M, et al. Analgesic efficacy and pharmacokinetics of ketoprofen administered into a surgical site. J Clin Pharmacol 1999; 39 (2): 131–8PubMedCrossRefGoogle Scholar
  40. 40.
    Patel RK, Leswell PF. Comparison of ketoprofen, piroxicam, and diclofenac gels in the treatment of acute soft-tissue injury in general practice. Clin Ther 1996; 18 (3): 497–507PubMedCrossRefGoogle Scholar
  41. 41.
    Airaksinen O, Venalainen J, Pietilainen T. Ketoprofen 2.5% gel versus placebo gel in the treatment of acute soft tissue injuries. Int J Clin Pharmacol Ther Toxicol 1993; 31 (11): 561–3PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Service de RhumatologieCHU RangueilToulouse Cedex 9France

Personalised recommendations